Vendor Intelligence Report: Xingtai Lesda Technology

Published 13 Jun 2026. 19-page investigative report on who is behind Xingtai Lesda Technology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 6 Finnrick lab tests, Xingtai Lesda Technology’s overall pass rate is 83% (5 pass / 1 fail). The signal is narrow: every tested sample is Retatrutide, not the wider marketplace catalog. The record is pass-heavy, but the failure mode matters — the file identifies one no-Retatrutide sample, plus quantity variance and batch-label inconsistencies. Ratings also weaken under stricter grading, which matters for cautious GLP-1 titration.

The corporate file is thinner than the marketing. Lesda’s GlobalSources profile lists a 2025 establishment year while claiming 10+ years of export experience. The dossier follows an older Lesda domain back to an unrelated business, then checks the claimed in-house chemical plant against the Tianyi City address, staff/capital bands, and lack of visible certifications.

The transaction posture is buyer-relevant: a marketplace-led China export channel, platform caution around WhatsApp/WeChat contact, irreversible payment rails, and customs-clearance language around GLP-1 products. The report separates Lesda-specific evidence from context: FDA Import Alert 66-80 is material to Retatrutide shipments, while the CBP seizure record is enforcement context rather than a Lesda allegation.

Bottom line: Lesda is not a blanket avoid based on Finnrick’s Retatrutide record; most tested samples contained the expected peptide. It is also not a trust-the-vendor-COA source. A buyer using Lesda would need batch-specific independent testing and coherent labels before treating any vial as usable, and Finnrick’s data gives no product-specific reassurance for the rest of the catalog.

Inside the full report:

  • Retatrutide test appendix for the single tested product, including batch IDs, quantity variance, and methodology-divergence charts
  • GlobalSources exhibits covering establishment year, export-experience claim, staff band, capitalization, contact, and platform warning
  • Domain-history analysis showing why the old Lesda name is not operating history for the peptide seller
  • Tianyi City operating-location review against the claimed in-house chemical plant
  • FDA Import Alert 66-80, CBP enforcement context, import-record searches, and payment-recourse analysis
  • Xingtai peptide-cluster comparison covering template, catalog, and regional overlap signals

Risk assessment

  • Retatrutide quality-control risk — high: Finnrick tested Retatrutide 6 times (5 pass / 1 fail) with 80.16% rating; field notes identify the fail as a no-Retatrutide sample and describe batch/label controls gaps.
  • Misleading manufacturer and operating-history claims — high: GlobalSources lists Year Established: 2025 while the profile claims >10 years export experience and a product listing claims an own chemical plant at a Tianyi City office/apartment address.
  • U.S. customs/regulatory seizure risk for GLP-1 shipments — high: Retatrutide/GLP-1 bulk substances from unapproved Chinese facilities fall under FDA Import Alert 66-80 DWPE; Lesda was not Green-Listed and no U.S. import records under its exact name were found.
  • Official-channel and authenticity-verification risk — medium: No active independent Lesda website was confirmed; lesda.com has unrelated historic ownership; GlobalSources warns it cannot guarantee WhatsApp/WeChat information.
  • Irreversible-payment recourse risk — medium: Product listing accepts Bitcoin, USDT and Western Union, leaving little chargeback/remediation leverage.